Table 2.
Variables | Total (n=80) | SNHG12, n (%) | P-value | |
---|---|---|---|---|
High Expression (n=40) | Low Expression (n=40) | |||
Age, year | ||||
<60 | 39 | 21 (52.5) | 18 (45.0) | 0.502 |
≥60 | 41 | 19 (47.5) | 22 (55.0) | |
Gender | ||||
Male | 40 | 24 (54.5) | 16 (44.4) | 0.369 |
Female | 40 | 20 (45.5) | 20 (55.6) | |
B symptoms | ||||
Absent | 40 | 19 (57.6) | 21 (44.7) | 0.256 |
Present | 40 | 14 (42.4) | 26 (55.3) | |
Stages | ||||
I-II | 45 | 16 (40.0) | 29 (72.5) | 0.003 |
III-IV | 35 | 24 (60.0) | 11 (27.5) | |
Extra-nodal invasion | ||||
Yes | 49 | 30 (75.0) | 19 (47.5) | 0.012 |
No | 31 | 10 (25.0) | 21 (52.5) | |
Serum LDH | ||||
<300 | 39 | 14 (35.0) | 25 (62.5) | 0.014 |
≥300 | 41 | 26 (65.0) | 15 (37.5) | |
IPI score | ||||
0–2 | 31 | 14 (35.0) | 17 (42.5) | 0.491 |
3–5 | 49 | 26 (65.0) | 23 (57.5) |
Note: P < 0.05 is showed in bold.
Abbreviations: DLBCL, diffuse large B-cell lymphoma; LDH, lactate dehydrogenase; IPI, International Prognostic Index.